Extended Nucleic Acid Therapeutics: Unlocking potential through tiny methylene chemical modifications

December 5th, 2025|Categories: Upcoming Webinars|

Date: April 2, 2026Time: 11-12pm EDT / 5-6pm CEST Register Here Title: Extended Nucleic Acid Therapeutics: Unlocking potential through tiny methylene chemical modifications Description: Modulation of the backbone structures of oligonucleotides has a profound impact on the pharmacokinetics and pharmacodynamics of RNA medicines. In ...

Advancing Prime Editing–Based Genome Editing Technologies for Therapeutic Applications

November 30th, 2025|Categories: Upcoming Webinars|

Date: March 26, 2026 Time: 12-1pm EDT / 5-6pm CET Register Here Title: Advancing Prime Editing–Based Genome Editing Technologies for Therapeutic Applications Description: In this webinar, I will discuss recent advances in prime editing–based genome engineering, including split prime editing, template-jumping prime ...

Trainee Spotlight Series: 2025 Oligo Meeting Poster Winners 3

November 30th, 2025|Categories: Upcoming Webinars|

Date: February 26, 2026 Time: 11am-12pm EST / 5-6pm CET Register Here Title: Combinational modulation of DNA Mismatch Repair protein ratios alter CAG repeat instability in hTERT-RPE1 cellular model Description: The somatic expansion of an unstable CAG trinucleotide repeat tract located within ...

Acute CNS Responses to centrally Delivered Oligonucleotides

November 30th, 2025|Categories: Upcoming Webinars|

Date: January 29, 2026Time: 11am-12pm EST / 5-6pm CET Register Here Title: Acute CNS Responses to centrally Delivered Oligonucleotides Description: Oligonucleotides delivered into cerebrospinal fluid elicit two independent, short-lived CNS phenotypes: an immediate neuronal activation phenotype that appears within minutes and resolves ...

Trainee Spotlight Series: 2025 Oligo Meeting Poster Winners 2

November 30th, 2025|Categories: Upcoming Webinars|

Date: January 15, 2026 Time: 11am-12pm EST / 5-6pm CET Register Here Title: Sustained muscle function improvement after a single in vivo dose of antibody oligonucleotide conjugate (AOC) in the mdx mouse model for Duchenne muscular dystrophy Description: Duchenne muscular dystrophy results ...

Go to Top